Events
Duane Morris Partner Richard T. Ruzich to Be Panelist at CBI's Pharmaceutical Congress on Paragraph IV Disputes
October 16, 2008 | Philadelphia
| Mariott Philadelphia Downtown
Duane Morris partner Richard T. Ruzich will be a panelist at the Center for Business Intelligence's Pharmaceutical Congress on Paragraph IV Disputes: Navigating Regulations and Enforcement Trends to Increase Preparedness and Optimize Paragraph IV Strategies, to be held on October 15-16, 2008, in Philadelphia, Pennsylvania. Mr. Ruzich will be participating in a panel discussion on the topic of "Implications of Recent Developments and Trends in Litigating Paragraph IV Disputes" on Thursday, October 16, at 8:15 a.m.
About the Panel Discussion
The world of pharmaceutical patent litigation has seen some exciting times as of late. The constantly changing landscape is enough to make your head spin just by following it, let alone trying to boil it down into understandable, relatable and applicable information for your business strategies. And besides, who has the time for this when most of us are busy contributing to the chaos? This panel of experts pulls together recent paragraph IV developments, and ones coming down the pipeline, to provide an in-depth analysis of their outcomes, means of getting these outcomes and the current and future effects on your business strategies.
- Declaratory judgments — The effects of MMA and Caraco and the impact in first filer's exclusivity rights
- Discussion of old standard — Teva v. Pfizer 2005
- Teva USA v. Novartis 2007
- At risk launches — Why are they becoming more common and will this trend continue?
- Willfulness — Abbott v. Sandoz 2007
- Preliminary injunctions — Novartis v. Teva 2007 and Altana v. Teva 2007
- The impact of forfeiture provisions on industry as a whole
- Expectations for the future of authorized generics
- Learning when to use KSR — Takeda v. Alphapharm 2007 and Ortho-McNeils v. Mylan 2008
- How the PREA Act has affected ANDA suitability petitions
About CBI's Pharmaceutical Congress on Paragraph IV Disputes
Paragraph IV litigation is reaching an all-time high with almost $85 billion in product sales that potentially could be affected by pending litigation and more than twenty-five drugs going off patent before 2012. Today's pharmaceutical companies, both brand and generic, have much at stake in this costly, complex and constantly changing area of patent litigation. CBI's Pharmaceutical Congress on Paragraph IV Disputes brings both sides of the issue together for two days of presentations and panel discussions to discuss litigation strategies, statutory guidelines, current cases and their landmark decisions. This timely and valuable content is designed to provide you with the information you need to know today for better business decisions tomorrow.
Attendees of the conference are also invited to attend a networking reception on October 15 at the conclusion of the day's activities.
For more information or to register to attend the conference, please call 1.800.817.8601 or visit CBI's website.
Mention promotional code RCX664 and save $500.
